China's Draft Cell Therapy Guidelines Draws Concern From Industry

New draft guidelines could potentially create parallel clinical pathways for cell and gene therapies in China, and industry executives are worried about different standards for such emerging treatments in a country with the highest number of ongoing cell therapy trials in the world.

CHINA CDE'S SENIOR REVIEWER HUANG HONGYUN AT CHINA RARE DISEASE SUMMIT LAST SEPTEMBER • Source: The Pink Sheet

China has now passed the US as the country with the highest number of clinical trials, but a recent new draft regulation from the Asian country’s top health regulator could open up a route to varying standards for the same type of products.

The draft, issued March 28 by China's ministry of health and the National Health Commission (NHC), officially outlined requirements and...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from China

More from Asia